Abstract: A novel composition and kit for a bone void filler are provided. The improved bone void filler includes a porous, collagen scaffolding admixed with calcium phosphate and at least one stabilizer agent. Optionally, the bone void filler further includes at least one bioactive agent.
Abstract: A method of conducting an endoscopic observation of an inner wall of a gastrointestine by applying a diagnostic agent to the inner wall of the gastrointestine, the diagnostic agent being an acidic aqueous solution of pH 1 to 5 containing a colorant, and conducting the endoscopic observation of the inner wall. The acidic aqueous solution can contain at least one acid selected from a carboxylic acid, hydrochloric acid, sulfuric acid and phosphoric acid. By applying the diagnostic agent to the inner wall of the gastrointestine in the endoscopic observation, it is possible to clearly observe a lesion which is difficult to be determined. In particular, the method can be used for observing lesions having cancer cells in the stomach or the Barrett's esophagus.
Type:
Grant
Filed:
August 4, 2011
Date of Patent:
March 5, 2013
Assignee:
National University Corporation Okayama University
Abstract: Methods for making comb-type antithrombotic conjugate wherein substantially all side chains of water soluble poly(vinyl alcohol) (PVA) are extended by ring-opening polymerization to form a copolymer wherein substantially all terminals are conjugated to an antithrombotic molecule. In addition, a method is provided for applying a coating comprising a comb-type anti-thrombotic conjugate to at least a portion of an implantable device to prevent or reduce the formation of thrombosis on the surface of the device. A first or sub-layer of the coating is prepared by mixing a polymeric material and a biologically active agent with a solvent, thereby forming a homogeneous solution. A second or outer layer comprising a comb-type anti-thrombotic conjugate may be applied over the inner drug-containing layers using, for example, a dip coating or spray coating process.
Abstract: The present invention relates to implantable medical devices coated with polymer having hemocompatible and/or prohealing moieties appended thereto and to their use in the treatment of vascular diseases.
Abstract: The invention is related to a sol-gel nanostructured titania reservoir and its synthesis which is biocompatible with brain tissue. The pore size distribution, crystallite size and the extent of the crystalline phase distribution of anatase, brookite and rutile can be fully controlled. This device may be used to contain neurological drugs. It may be inserted directly into brain tissue for the purpose of the controlled time release of drugs over a period of from 6 months to three years.
Abstract: A therapeutic-agent release region is described, which comprises: (i) a first phase comprising a plurality of miscible polymers that are miscible with one another and (ii) a second phase comprising an additional polymer, which can be immiscible with any or all of the plurality of miscible polymers or a blend of the miscible polymers. Also described is a therapeutic-agent-releasing medical device, which comprises: (a) an implantable or insertable medical device substrate; (b) the above release region, disposed over at least a portion of the implantable or insertable medical device substrate, and (c) a therapeutic agent. The release region regulates the rate of release of the therapeutic agent from the medical device upon implantation or insertion of the device into a patient. Also described are methods for making an implantable or insertable medical device, for administering a therapeutic agent to a patient, and for modulating the release rate of a therapeutic agent.
Abstract: A system comprising an implantable medical device and a second polymeric layer configured to be disposed on or about the implantable medical device is described. The device includes a first polymeric layer into which a first therapeutic agent is incorporated. A second therapeutic agent is incorporated into the second polymeric layer. The device is sterilized by a first sterilization method. The second polymeric layer is sterilized by a second sterilization method. A method for making a sterile implantable medical system is also described. The method includes incorporating a first therapeutic agent in a first polymeric material and disposing the first polymeric material on or about an implantable medical device. The first polymeric material and the implantable medical device are sterilized by a first sterilization method.
Type:
Grant
Filed:
September 27, 2006
Date of Patent:
October 30, 2012
Assignee:
Medtronic, Inc.
Inventors:
Thomas C Bischoff, Jennifer E Raeder-Devens
Abstract: A coated medical device an a method of providing a coating on an implantable medical device result in a medical device having a bio-absorbable coating. The coating includes a bio-absorbable carrier component. In addition to the bio-absorbable carrier component, a therapeutic agent component can also be provided. The coated medical device is implantable in a patient to effect controlled delivery of the coating, including the therapeutic agent, to the patient.
Type:
Grant
Filed:
September 28, 2005
Date of Patent:
September 11, 2012
Assignee:
Atrium Medical Corporation
Inventors:
Roger Labrecque, Geoffrey Moodie, Joseph Ferraro, Lisa Rogers, Paul Martakos, Theodore Karwoski, Steve A. Herweck
Abstract: A system and compositions including zotarolimus and paclitaxel are disclosed, as well as methods of delivery, wherein the drugs have effects that complement each other. Medical devices are disclosed which include supporting structures that include at least one pharmaceutically acceptable carrier or excipient, which carrier or excipient can include one or more therapeutic agents or substances, with the carrier including at least one coating on the surface thereof, and the coating associated with the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature.
Type:
Grant
Filed:
August 15, 2006
Date of Patent:
September 4, 2012
Assignee:
Abbott Laboratories
Inventors:
Sandra E. Burke, Keith R. Cromack, Matthew Mack, John L. Toner
Abstract: An minimum risk liquid natural insect repellent which comprises citronellal java type oil as the active repellency for the use against biting gnats and the inactive ingredient is low viscosity white mineral oil petroleum type and is a secondary means of protection, and isopropyl myristate as the emulsifier. In a process which consists of a free gas injection vacuum batch mixture procedure.
Abstract: Biocompatible implants including a polymer substrate and a reactive component for implant fixation in situ. The reactive component in combination with the substrate creates a reactive implant which bonds to a tissue surface in situ.
Abstract: Any pharmaceutical preparation for oral administration with controlled release of active ingredient in the small bowel, on the basis of active ingredient carriers provided with at least one active ingredient which are provided with an inner layer to control the release of active ingredient and with a gastro-resistant coating layer disposed thereon, which is characterized in that the inner layer is formed from at least two diffusion layers whose permeability for the diffusing active ingredient decreases from the inside to the outside, and a method for the production thereof, are described.
Type:
Grant
Filed:
July 5, 2007
Date of Patent:
July 17, 2012
Assignee:
Dr. Robert Pfleger Chemische Fabrik GmbH
Abstract: The present invention relates to methods for coating at least one surface of a medical device for improving the hemocompatibility of said surface. Further, the invention relates to medical devices comprising surfaces, coated with a coating composition containing a nonionic ester formed from an acyclic C3-C6(OH)3-6 polyol and from at least three C12-C26 fatty acids, and further includes at least one hydrophilic group.
Abstract: The present invention relates to implantable medical devices coated with polymer having hemocompatible and/or prohealing moieties appended thereto and to their use in the treatment of vascular diseases.
Abstract: In certain embodiments provided are composition suitable for cleansing or treating the skin, the composition comprising: (i) at least 90% water; (ii) a non-ionic surfactant; (iii) one or more hydrophobic emollients present in a concentration from about 200 parts per million (ppm) to about 4000 ppm, and wherein the composition has a ratio of total surfactant concentration to total hydrophobic emollient concentration that is from about 0.5 to about 2.5. In other embodiments, provided are articles comprising a water-insoluble absorbent substrate and a composition comprising a polyol polyhydroxystearate or a water-soluble glyceryl polyacrylate impregnated therein.
Type:
Grant
Filed:
December 4, 2008
Date of Patent:
May 8, 2012
Assignee:
Johnson & Johnson GmbH
Inventors:
Pietro Rosato, Rainer Lange, Johannes Crotogino
Abstract: A method is disclosed for the generation of bone tissue by the preparation and the application to bone defect sites of a resorbable silica-calcium phosphate bioactive composite (SCPC) that finds utility as a bone tissue engineering scaffold. The resorbable silica-calcium phosphate bioactive composite can be applied directly to bone defect or can be employed as a bioactive coating on implants to facilitate bone growth around the implant. The resorbable silica-calcium phosphate bioactive composite is prepared from a mixture of a silica salt in an amount to provide between about 0.31 moles and about 0.93 moles of silica and calcium phosphate, said silica salt being present in the resorbable silica-calcium phosphate bioactive composite. The mixture is thermally treated at a temperature ranging between about 130° C. to about 1200° C. to form said resorbable silica-calcium phosphate bioactive composite having a phase composition comprising a thermally treated form of silica and calcium phosphate.
Abstract: The present invention encompasses a coating on the surface of a substrate and the coated substrates. The coating includes a polymer, an olimus drug (sirolimus, everolimus, zotarolimus, etc.), and a dexamethasone derivative. The polymer may be a hydrophobic polymer, preferably a fluoropolymer, and more preferably a fluoropolymer with at least 25% vinylidene fluoride by weight.
Type:
Grant
Filed:
September 29, 2008
Date of Patent:
January 10, 2012
Assignee:
Abbott Cardiovascular Systems Inc.
Inventors:
Stephen D. Pacetti, John L. Toner, Keith R. Cromack
Abstract: The present invention provides a physiologically compatible conductive agent comprising (a) a long chain water-soluble ionic polymeric thickening agent selected from the group consisting of a copolymer of methyl vinyl ether and maleic anhydride, carboxy polymethylene polymer, and mixtures thereof, present in an amount from about 0.05 wt. % to about 10 wt. %; (b) an unbranched or branched alcohol having from 1 to about 4 carbon atoms present in an amount up to about 70 wt. %; and (c) the balance water. The present invention also provides a physiologically compatible conductive agent comprising long chain water-soluble ionic polymeric thickening agent selected from the group consisting of a copolymer of methyl vinyl ether and maleic anhydride, carboxy polymethylene polymer, and mixtures thereof, present in an amount from about 0.05 wt. % to about 10 wt. %; (b) a surface tension reducing amount of a surfactant; and (c) the balance water.
Abstract: This invention relates to compositions containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, characterized in that said composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. This invention also relates to ophthalmic oil-in-water emulsions containing such compositions, said ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.
Type:
Grant
Filed:
July 9, 2007
Date of Patent:
December 6, 2011
Assignee:
Novagli Pharma S.A.
Inventors:
Laura Rabinovich-Guilatt, Gregory Lambert, Frederic Lallemand, Betty Philips
Abstract: A firm but pliable medical device for use as a bone graft substitute or bone graft extender retains its shape without the requirement of a containment device, such as a syringe. Because the device is solid, it is easy to locate or position in-vivo and, in the moist environment of the body, it will hold its shape well, for an extended time. Because the lyophilized pliable medical device is porous, it adsorbs blood and other beneficial cells containing body fluids, such as bone marrow, contributing to its superior bone repair efficacy in comparison to an analogous putty that has not been lyophilized. In addition these lyophilized pliable medical devices are easier to terminally steam sterilize than the analogous putty because there is no moisture present to boil and “blow-out” of the containment device (syringe). The glycerin that is present in the formulation lends pliability but has a low vapor pressure.
Type:
Grant
Filed:
December 16, 2005
Date of Patent:
November 1, 2011
Assignee:
Cerapedics, Inc.
Inventors:
James John Benedict, Greg Allen Brewster, Donald Barclay Freeman